Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis.
Cancer is a disease driven by a combination of inherited risk alleles coupled with the acquisition of somatic mutations, including amplification and deletion of genomic DNA. Potential relationships between the inherited and somatic aspects of the disease have only rarely been examined on a genome-wide level. Applying a novel integrative analysis of SNP and copy number measurements, we queried the tumor and normal-tissue genomes of 178 glioblastoma patients from the Cancer Genome Atlas project for preferentially amplified alleles, under the hypothesis that oncogenic germline variants will be selectively amplified in the tumor environment. Selected alleles are revealed by allelic imbalance in amplification across samples. This general approach is based on genetic principles and provides a method for identifying important tumor-related alleles. We find that SNP alleles that are most significantly overrepresented in amplicons tend to occur in genes involved with regulation of kinase and transferase activity, and many of these genes are known contributors to gliomagenesis. The analysis also implicates variants in synapse genes. By incorporating gene expression data, we demonstrate synergy between preferential allelic amplification and expression in DOCK4 and EGFR. Our results support the notion that combining germline and tumor genetic data can identify regions relevant to cancer biology.
LaFramboise
Thomas
T
Department of Genetics, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Dewal
Ninad
N
Wilkins
Katherine
K
Pe'er
Itsik
I
Freedman
Matthew L
ML
D000483:Alleles; D066246:ErbB Receptors / Q000235:genetics; D020690:GTPase-Activating Proteins / Q000235:genetics; D005784:Gene Amplification / Q000235:genetics*; D015894:Genome, Human / Q000235:genetics; D005854:Germ Cells / Q000378:metabolism*; D005909:Glioblastoma / Q000235:genetics* / Q000473:pathology; D006801:Humans; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D012641:Selection, Genetic
C510122:DOCK4 protein, human; D020690:GTPase-Activating Proteins; D066246:ErbB Receptors
Cancer Res. 2008 Jan 1;68(1):14-7
18172290
Cancer Res. 2003 Aug 15;63(16):4849-53
12941805
Am J Hum Genet. 1993 Mar;52(3):506-16
8447318
Nat Genet. 2003 Aug;34(4):403-12
12881723
Nat Genet. 2008 Oct;40(10):1240-4
18758463
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
5279523
Nat Genet. 2010 May;42(5):454-8
20400965
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13
1584765
Nat Genet. 2009 Apr;41(4):455-9
19287384
Sci Signal. 2009 Sep 08;2(87):re6
19738203
Nat Genet. 2009 Apr;41(4):446-9
19287382
Cell Oncol. 2007;29(5):399-408
17726262
Nat Genet. 2009 Aug;41(8):905-8
19578366
J Neurosci Res. 2008 Nov 1;86(14):3052-61
18615735
Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903
3477813
Nat Rev Mol Cell Biol. 2008 Sep;9(9):690-701
18719708
Nat Genet. 2003 Mar;33(3):357-65
12567188
Cancer Cell. 2010 Jan 19;17(1):98-110
20129251
PLoS Comput Biol. 2005 Nov;1(6):e65
16322765
Bioinformatics. 2010 Feb 15;26(4):518-28
20031965
Cancer Res. 2007 Aug 1;67(15):7203-11
17671188
Clin Cancer Res. 2008 Feb 15;14(4):957-60
18281526
J Pathol. 2007 Mar;211(4):481-8
17294421
Nat Genet. 2000 May;25(1):25-9
10802651
Nat Genet. 2009 Apr;41(4):450-4
19287385
Br J Cancer. 2009 Dec 15;101(12):1995-2004
19904263
Clin Cancer Res. 2009 Oct 1;15(19):6258-66
19789313
Am J Pathol. 2007 May;170(5):1445-53
17456751
Cell. 2003 Mar 7;112(5):673-84
12628187
Neuro Oncol. 2007 Jul;9(3):291-7
17504929
Science. 1976 Oct 1;194(4260):23-8
959840
Nature. 2008 Oct 23;455(7216):1061-8
18772890
Bioinformatics. 2008 Jul 15;24(14):1650-1
18511468
Nat Genet. 2006 Aug;38(8):904-9
16862161
N Engl J Med. 2005 Nov 10;353(19):2012-24
16282176
Int J Cancer. 2006 Jan 15;118(2):505-8
16049965
Oncogene. 2007 Jun 14;26(28):4171-8
17311004